TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30

Twist Bioscience Corp

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$139.77+7.02 (+5.29%)

Close on Oct 19, 2026

Market cap: $8.72B
P/E (TTM): –
Dividend yield: –

Twist Bioscience Corp income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30	FY 2020 2020-09-30	FY 2019 2019-09-30	FY 2018 2018-09-30	FY 2017 2017-09-30	FY 2016 2016-09-30
Revenue	377	313	245	204	132	90	54	25	11	–
Cost of Revenue	186	180	155	119	81	61	47	32	24	–
Gross Profit	191	133	90	84	52	29	6.96	-6.76	-13	–
Research & Development	80	91	107	120	69	43	36	20	19	–
Selling, General & Admin	247	218	190	213	136	103	80	43	26	–
Advertising Expenses	7.00	5.20	2.90	2.40	2.50	1.20	1.30	0.00	0.10	–
Total Costs & Expenses	513	534	462	438	285	230	163	96	69	–
Operating Income	-136	-221	-217	-235	-153	-140	-109	-71	-58	–
Interest Expense	–	0.03	0.01	0.08	0.37	0.79	1.29	1.31	0.91	–
Interest & Investment Income	11	15	14	3.06	0.44	1.50	3.03	1.00	0.41	–
Other Non-Operating Income	-0.90	-2.68	-0.67	-1.09	-1.37	-0.18	-0.27	-0.12	-0.06	–
Merger & Restructuring Charges	0	0	9.38	0	0	–	–	–	–	–
Asset Impairment Charges	0	45	6.79	0	–	0	0	0	–	0
Gain (Loss) on Sale of Assets	0	-45	-6.79	0	0	0	-0.19	-0.06	-0.51	–
Legal Settlements	–	–	–	0	0	-23	–	–	–	–
Pretax Income	-77	-208	-203	-228	-154	-140	-107	-71	-59	–
Income Tax Expense	0.72	0.56	1.15	-10	-1.93	0.38	0.29	0.24	0.28	–
Net Income incl. Noncontrolling Interests	-78	-209	-205	-218	-152	-140	-108	-71	-59	–
Net Income	-78	-209	-205	-218	-152	-140	-108	-71	-59	–
EPS (Basic)(per share)	-1.30	-3.60	-3.60	-4.04	-3.15	-3.57	-3.92	-25.51	-24.49	–
EPS (Diluted)(per share)	-1.30	-3.60	-3.60	-4.04	-3.15	-3.57	-3.92	-25.51	-24.49	–
Shares Outstanding (Basic, Weighted)(shares)	60	58	57	54	48	39	27	0.00	2,422	–
Shares Outstanding (Diluted, Weighted)(shares)	60	58	57	54	48	39	27	0.00	2,422	–
EBITDA	-111	-189	-188	-218	-143	-133	-103	-65	-53	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 52.0%
Operating margin: -33.6%
Net margin: -31.7%
Return on equity, FY2025: -16.4%

Financial strength

Current ratio: 2.67
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 97.7%

Valuation

P/E ratio: –
Price to sales: 20.20
Price to book: 19.57
Dividend yield: –